Using Doxorubicin-Eluting Beads for Liver Cancer Treatment
Author Information
Author(s): Ouzreiah Nawawi, Hazman MN, Abdullah BJJ, Vijayananthan A, Manikam J, Mahadeva S, Goh KL
Primary Institution: Department of Biomedical Imaging, University of Malaya
Hypothesis
This study evaluates the effectiveness and safety of doxorubicin-eluting beads (DEB) in treating patients with early and intermediate hepatocellular carcinoma (HCC).
Conclusion
DEB TACE is safe and effective in a select group of patients, with improved survival when combined with other treatment modalities.
Supporting Evidence
- The objective response rate was 57.9% at 1 month and 50% at 1 year.
- The 1-year survival rate in the DEB TACE only group was 80%.
- Complications occurred in 21.1% of patients, with a 5.3% 30-day mortality rate.
Takeaway
Doctors used special beads that release medicine to help treat liver cancer, and they found it worked well for many patients.
Methodology
This retrospective cohort study reviewed 19 patients with HCC who underwent DEB transarterial chemoembolisation (TACE) and followed their outcomes through imaging.
Limitations
The study is limited by its small sample size and retrospective design.
Participant Demographics
84.2% male, 15.8% female, mean age 59.2 years.
Statistical Information
P-Value
p=0.03 for alanine aminotransferase, p=0.002 for aspartate aminotransferase.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website